Maze Therapeutics (MAZE) Competitors $12.78 -0.09 (-0.70%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. NAMS, AMRX, RXRX, KNSA, VCEL, GMTX, DNLI, CGON, HRMY, and AGIOShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Gemini Therapeutics (GMTX), Denali Therapeutics (DNLI), CG Oncology (CGON), Harmony Biosciences (HRMY), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors NewAmsterdam Pharma Amneal Pharmaceuticals Recursion Pharmaceuticals Kiniksa Pharmaceuticals Vericel Gemini Therapeutics Denali Therapeutics CG Oncology Harmony Biosciences Agios Pharmaceuticals Maze Therapeutics (NASDAQ:MAZE) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking. Which has better earnings & valuation, MAZE or NAMS? Maze Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M3.34N/AN/AN/ANewAmsterdam Pharma$47.14M48.82-$176.94M-$1.88-10.90 Does the MarketBeat Community believe in MAZE or NAMS? NewAmsterdam Pharma received 24 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 90.91% of users gave NewAmsterdam Pharma an outperform vote. CompanyUnderperformOutperformMaze TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesNewAmsterdam PharmaOutperform Votes3090.91% Underperform Votes39.09% Does the media refer more to MAZE or NAMS? In the previous week, NewAmsterdam Pharma had 27 more articles in the media than Maze Therapeutics. MarketBeat recorded 30 mentions for NewAmsterdam Pharma and 3 mentions for Maze Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.53 beat Maze Therapeutics' score of 0.47 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 10 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in MAZE or NAMS? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MAZE or NAMS more profitable? Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A NewAmsterdam Pharma N/A N/A N/A Do analysts prefer MAZE or NAMS? Maze Therapeutics currently has a consensus price target of $25.67, suggesting a potential upside of 100.83%. NewAmsterdam Pharma has a consensus price target of $43.00, suggesting a potential upside of 109.76%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNewAmsterdam Pharma beats Maze Therapeutics on 8 of the 12 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$559.73M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E RatioN/A33.3227.1720.06Price / Sales3.34469.84410.88157.10Price / CashN/A168.6838.2534.64Price / BookN/A3.457.094.70Net IncomeN/A-$72.35M$3.23B$247.88M7 Day Performance-4.20%6.23%2.91%2.66%1 Month Performance26.16%16.53%9.09%6.40%1 Year PerformanceN/A-16.90%31.75%14.07% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$12.78-0.7%$25.67+100.8%N/A$559.73M$167.50M0.00121NAMSNewAmsterdam Pharma2.9856 of 5 stars$20.14+3.2%$42.86+112.8%+3.2%$2.26B$47.14M-10.714Trending NewsAnalyst ForecastAnalyst RevisionAMRXAmneal Pharmaceuticals3.7149 of 5 stars$7.62+6.3%$11.60+52.2%+10.7%$2.25B$2.83B-11.217,600Positive NewsRXRXRecursion Pharmaceuticals1.9245 of 5 stars$5.49+20.1%$7.60+38.4%-37.1%$2.23B$59.82M-3.59400Trending NewsGap UpHigh Trading VolumeKNSAKiniksa Pharmaceuticals3.2478 of 5 stars$30.23+2.4%$38.80+28.3%+61.1%$2.21B$481.17M-215.91220Trending NewsInsider TradeHigh Trading VolumeVCELVericel2.67 of 5 stars$43.30-0.2%$61.14+41.2%+2.0%$2.18B$238.54M721.79300Positive NewsGMTXGemini TherapeuticsN/A$50.02+4.2%N/A+33.6%$2.17BN/A-50.0230DNLIDenali Therapeutics4.3524 of 5 stars$14.70+3.4%$33.71+129.3%-29.7%$2.14B$330.53M-5.33430Positive NewsAnalyst RevisionCGONCG Oncology2.4986 of 5 stars$26.91+1.1%$58.22+116.4%-25.6%$2.05B$662K-17.8261Positive NewsAnalyst RevisionHRMYHarmony Biosciences4.7766 of 5 stars$35.60+1.6%$53.00+48.9%+18.4%$2.04B$744.85M16.87200Positive NewsShort Interest ↑Analyst RevisionAGIOAgios Pharmaceuticals4.0248 of 5 stars$34.33+2.2%$56.50+64.6%-27.6%$1.99B$37.04M3.03390Positive NewsAnalyst Revision Related Companies and Tools Related Companies NewAmsterdam Pharma Competitors Amneal Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors Kiniksa Pharmaceuticals Competitors Vericel Competitors Gemini Therapeutics Competitors Denali Therapeutics Competitors CG Oncology Competitors Harmony Biosciences Competitors Agios Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
